Swiss-based Santhera Pharmaceuticals has partnered with Cold Spring Harbor Laboratory (CSHL) to explore the use of lonodelestat (POL6014) as a potential treatment for acute respiratory distress syndrome (ARDS) caused by Covid-19.

CSHL researchers joined a new consortium of international non-clinical and clinical experts called ‘NETwork to target neutrophils in Covid-19’.

The consortium will analyse the role of neutrophils and neutrophil extracellular traps (NETs) in the Covid-19 pathology, while also investigating hNE and other targets for the treatment of the novel coronavirus infection.

NETs are macromolecular DNA structures and proteins that neutrophils can expel; hNE is generated by neutrophils during NETs formation.

Santhera noted similarities between the clinical presentation of severe Covid-19 and NETs-drive diseases such as ARDS.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Based on similarities, the consortium believes that excess NETs may be associated with Covid-19 and hNE inhibition may help inhibit NETs in these patients.

Cold Spring Harbor Laboratory associate professor Mikala Egeblad said: “There is a strong scientific rationale that inhibition of hNE may interrupt a neutrophil-driven inflammatory cascade that leads to ARDS in Covid-19 patients.

“Based on previous work with lonodelestat in models of ARDS and acute lung injury, we were very encouraged about the potential of lonodelestat.”

Santhera will supply lonodelestat, as well as offer intellectual support to CSHL, which will immediately begin the non-clinical research programme.

The programme is intended to validate hNE as a target and study lonodelestat as a potential Covid-19 therapeutic.

In preclinical studies, lonodelestat was effective in animal models of neutrophil activation in lung tissue and of acute lung injury (ALI).

The drug completed Phase I single-dose escalation trials in healthy volunteers and patients with cystic fibrosis (CF). It is currently being evaluated in a multiple ascending dose study in CF patients.